Biotech News
GSK to drive growth in emerging markets with acquisition of UCB products
GSK signed an agreement with UCB S.A to acquire its portfolio across Africa, the Middle East, Asia Pacific and Latin America, for €515 m.
Open original release
Related news
GSKGSK plc2026-06-25 13:46 EST
GSK announces commencement of tender offer to acquire Nuvalent, Inc.
GSKGSK plc2026-06-25 13:46 EST
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
GSKGSK plc2026-06-25 13:46 EST
GSK’s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome
GSKGSK plc2026-06-25 13:46 EST
GSK enters agreement to acquire Nuvalent, Inc.
GSKGSK plc2026-06-25 13:46 EST
Bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
GSKGSK plc2026-06-25 13:46 EST
GSK to showcase long-term outcomes and pipeline expansion with latest oncology research at ASCO and EHA
GSKGSK plc2026-06-25 13:46 EST
GSK’s RSV vaccine, Arexvy, receives expanded approval in Japan for adults aged 18–59 at increased risk
GSKGSK plc2026-06-25 13:46 EST
GSK enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch
GSKGSK plc2026-06-25 13:46 EST
GSK and Xenoport resubmit new drug application for Solzira™ in restless legs syndrome
GSKGSK plc2026-06-25 13:46 EST
GlaxoSmithKline receives European Commission approval to market alli® (orlistat 60mg)
GSK plc
GSK plc is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Recent company news
GSKGSK plc2026-06-26 06:08 EST
GSK announces commencement of tender offer to acquire Nuvalent, Inc.
GSKGSK plc2026-06-26 06:08 EST
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
GSKGSK plc2026-06-26 06:08 EST
GSK’s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome
GSKGSK plc2026-06-26 06:08 EST
GSK enters agreement to acquire Nuvalent, Inc.
GSKGSK plc2026-06-26 06:08 EST
Bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
Stock data
- Close
- —
- Market cap
- —
- Exchange
- NYSE
- Sector
- Biotechnology
- Location
- United States